BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa

Reuters10-29

BRIEF-Avalo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa

Oct 29 (Reuters) - Avalo Therapeutics Inc AVTX.O:

AVALO THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 LOTUS TRIAL OF AVTX-009 FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA
AVALO THERAPEUTICS - LOTUS TRIAL ENROLLS 250 PATIENTS, TOPLINE DATA FROM TRIAL IS EXPECTED IN MID-2026.

Source text: ID:nGNX3m7XSc

Further company coverage: AVTX.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579897410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579897410","market":"fut","top_or_hot":-1,"title":"BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa</title></head><body><p><span>Oct 29 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a> <span>AVTX.O</span>:</p><ul><li><p>AVALO THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 LOTUS TRIAL OF AVTX-009 FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA</p></li><li><p>AVALO THERAPEUTICS  - LOTUS TRIAL ENROLLS 250 PATIENTS, TOPLINE DATA FROM TRIAL IS EXPECTED IN MID-2026.</p></li></ul><p>Source text: <span>ID:nGNX3m7XSc</span></p><p>Further company coverage: <span>AVTX.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa</title></head><body><p><span>Oct 29 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a> <span>AVTX.O</span>:</p><ul><li><p>AVALO THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 LOTUS TRIAL OF AVTX-009 FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA</p></li><li><p>AVALO THERAPEUTICS  - LOTUS TRIAL ENROLLS 250 PATIENTS, TOPLINE DATA FROM TRIAL IS EXPECTED IN MID-2026.</p></li></ul><p>Source text: <span>ID:nGNX3m7XSc</span></p><p>Further company coverage: <span>AVTX.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA2VDXRV:1","article_id":"2579897410","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579897410","pubTimestamp":1761735878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis SuppurativaOct 29 (Reuters) - Avalo Therapeutics Inc AVTX.O:AVALO THERA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVTX":"Avalo Therapeutics Inc"},"translate_title":"简介-Avalo Therapeutics宣布完成AVTX-009治疗化脓性汗腺炎的2期LOTUS试验的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":0.9},"content_text":"BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis SuppurativaOct 29 (Reuters) - Avalo Therapeutics Inc AVTX.O:AVALO THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 LOTUS TRIAL OF AVTX-009 FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVAAVALO THERAPEUTICS  - LOTUS TRIAL ENROLLS 250 PATIENTS, TOPLINE DATA FROM TRIAL IS EXPECTED IN MID-2026.Source text: ID:nGNX3m7XScFurther company coverage: AVTX.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579897410","isCrawlerRequest":true}